Novartis Receives Permanent J-code for Beovu

Source: Novartis

Novartis announced that it has received a permanent J-code for Beovu (brolucizumab-dbll) injection, effective January 1, 2020.

With the permanent J-code, retina specialists may now receive more timely reimbursement for Beovu injections, facilitating access for appropriate patients to this medicine.

In October, Novartis received FDA approved for Beovu for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a 3-month dosing interval immediately after a 3-month loading phase, according to Novartis.

Related Content